Becton, Dickinson and Company (NYSE:BDX) Announces Quarterly Earnings Results, Beats Estimates By $0.43 EPS

Becton, Dickinson and Company (NYSE:BDX) announced its quarterly earnings results on Wednesday. The medical instruments supplier reported $3.43 earnings per share for the quarter, beating the consensus estimate of $3.00 by $0.43, Zacks reports. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. Becton, Dickinson and Company updated its FY 2025 guidance to 14.300-14.600 EPS.

Becton, Dickinson and Company Price Performance

Shares of NYSE:BDX traded up $2.65 during trading on Wednesday, reaching $245.07. The stock had a trading volume of 2,061,265 shares, compared to its average volume of 2,046,401. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.17. The business has a fifty day moving average price of $231.33 and a 200-day moving average price of $234.02. The stock has a market cap of $71.07 billion, a PE ratio of 41.26, a PEG ratio of 1.80 and a beta of 0.40. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $251.99.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be given a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.70%. The ex-dividend date is Monday, March 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 70.03%.

Becton, Dickinson and Company announced that its Board of Directors has initiated a share buyback program on Tuesday, January 28th that permits the company to repurchase 10,000,000 outstanding shares. This repurchase authorization permits the medical instruments supplier to purchase shares of its stock through open market purchases. Shares repurchase programs are usually a sign that the company’s board of directors believes its stock is undervalued.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Shana Carol Neal sold 788 shares of the business’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $235.00, for a total transaction of $185,180.00. Following the transaction, the executive vice president now owns 16,201 shares of the company’s stock, valued at approximately $3,807,235. The trade was a 4.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP David Shan sold 500 shares of the business’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $240.00, for a total value of $120,000.00. Following the transaction, the executive vice president now directly owns 5,741 shares in the company, valued at $1,377,840. This trade represents a 8.01 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 9,844 shares of company stock valued at $2,210,716 over the last ninety days. Insiders own 0.36% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on BDX shares. StockNews.com cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Piper Sandler lifted their price target on Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research report on Tuesday, January 28th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $283.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.